10.07.2014 • News

Biesterfeld expands its Executive Board

Biesterfeld AG expands its Executive Board from two to four members: beside Birger Kuck, CEO, and Christian Wolfsohn, CFO, Thomas Arnold, Managing Director of Biesterfeld Spezialchemie, and Carsten Harms, Managing Director of Biesterfeld Plastic, join the Executive Board, with immediate effect.
"With this decision the Supervisory Board emphasizes the importance of the operative businesses within the Group and in the Executive Board. We want to give the plastic and the chemicals activities an own voice in the executive board of Biesterfeld AG", explains Dirk Biesterfeld, chairman of the Supervisory Board. Arnold and Harms assume their function in the Executive Board with immediate effect while continuing in their resp. position as Managing Directors within the Biesterfeld Group.

Arnold (54) joined Biesterfeld in May 2013 as Managing Director of Biesterfeld Spezialchemie. Prior to this he held management positions in various renowned, international companies in the trade. Harms (48) has been with Biesterfeld since his trainee. He has driven the development of Biesterfeld Plastic as a one of the leading European distributors for plastics and rubber forward, since 2007 in the position as managing director of Biesterfeld Plastic.

Company

Logo:

Biesterfeld AG

Ferdinandstraße 41
20095 Hamburg
Germany

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read